Peregrine Pharmaceuticals Company Profile (NASDAQ:PPHM)

About Peregrine Pharmaceuticals (NASDAQ:PPHM)

Peregrine Pharmaceuticals logoPeregrine Pharmaceuticals, Inc. (Peregrine) is a biopharmaceutical company. The Company operates through two segments: Peregrine, which is engaged in the research and development of monoclonal antibodies for the treatment of cancer, and Avid, which is engaged in providing contract manufacturing services for third party customers on a fee-for-service basis while also supporting its internal drug development efforts. Bavituximab is its lead immunotherapy candidate. Bavituximab is a monoclonal antibody that targets and binds to phosphatidylserine (PS), a immunosuppressive molecule that is usually located inside the membrane of healthy cells, but then flips and becomes exposed on the outside of cells in the tumor microenvironment, causing the tumor to evade immune detection. The Company's subsidiary is Avid Bioservices, Inc. (Avid). Avid provides integrated current good manufacturing practices (cGMP) services from cell line development to commercial biomanufacturing.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biopharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NASDAQ:PPHM
  • CUSIP: N/A
  • Web: www.peregrineinc.com
Capitalization:
  • Market Cap: $207.32 million
  • Outstanding Shares: 45,069,000
Average Prices:
  • 50 Day Moving Avg: $4.33
  • 200 Day Moving Avg: $3.83
  • 52 Week Range: $1.96 - $5.78
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: Infinity
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $57.63 million
  • Price / Sales: 3.60
  • Book Value: $1.22 per share
  • Price / Book: 3.77
Profitability:
  • EBIDTA: ($25,800,000.00)
  • Net Margins: -48.86%
  • Return on Equity: -63.75%
  • Return on Assets: -25.31%
Debt:
  • Current Ratio: 1.42%
  • Quick Ratio: 0.70%
Misc:
  • Average Volume: 213,665 shs.
  • Beta: 2.53
  • Short Ratio: 1.69
 
Frequently Asked Questions for Peregrine Pharmaceuticals (NASDAQ:PPHM)

What is Peregrine Pharmaceuticals' stock symbol?

Peregrine Pharmaceuticals trades on the NASDAQ under the ticker symbol "PPHM."

When did Peregrine Pharmaceuticals' stock split? How did Peregrine Pharmaceuticals' stock split work?

Peregrine Pharmaceuticals's stock reverse split before market open on Monday, July 10th 2017. The 1-7 reverse split was announced on Friday, July 7th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 7th 2017. An investor that had 100 shares of Peregrine Pharmaceuticals stock prior to the reverse split would have 14 shares after the split.

How were Peregrine Pharmaceuticals' earnings last quarter?

Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) issued its earnings results on Friday, July, 14th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.07) by $0.09. The business had revenue of $17.90 million for the quarter, compared to the consensus estimate of $22.57 million. Peregrine Pharmaceuticals had a negative net margin of 48.86% and a negative return on equity of 63.75%. Peregrine Pharmaceuticals's revenue was down 4.8% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.05) EPS. View Peregrine Pharmaceuticals' Earnings History.

Where is Peregrine Pharmaceuticals' stock going? Where will Peregrine Pharmaceuticals' stock price be in 2017?

3 analysts have issued 1-year target prices for Peregrine Pharmaceuticals' shares. Their forecasts range from $3.50 to $7.00. On average, they expect Peregrine Pharmaceuticals' share price to reach $5.25 in the next year. View Analyst Ratings for Peregrine Pharmaceuticals.

Who are some of Peregrine Pharmaceuticals' key competitors?

Who are Peregrine Pharmaceuticals' key executives?

Peregrine Pharmaceuticals' management team includes the folowing people:

  • Carlton M. Johnson Jr., Independent Chairman of the Board
  • Steven W. King, President, Chief Executive Officer, Director
  • Paul J. Lytle, Chief Financial Officer
  • Mark R. Ziebell, Vice President, General Counsel, Corporate Secretary
  • Shelley P.M. Fussey Ph.D., Vice President - Intellectual Property
  • Joseph S. Shan, Vice President - Clinical & Regulatory Affairs
  • David H. Pohl, Independent Director
  • Eric S. Swartz, Independent Director

Who owns Peregrine Pharmaceuticals stock?

Peregrine Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include STAFFORD JOHN S III (7.80%), RONIN CAPITAL, LLC (7.80%), STAFFORD JOHN S III (7.30%), TAPPAN STREET PARTNERS LLC (5.10%) and Eqis Capital Management Inc. (0.35%). View Institutional Ownership Trends for Peregrine Pharmaceuticals.

Who bought Peregrine Pharmaceuticals stock? Who is buying Peregrine Pharmaceuticals stock?

Peregrine Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Eqis Capital Management Inc.. View Insider Buying and Selling for Peregrine Pharmaceuticals.

How do I buy Peregrine Pharmaceuticals stock?

Shares of Peregrine Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Peregrine Pharmaceuticals' stock price today?

One share of Peregrine Pharmaceuticals stock can currently be purchased for approximately $4.60.


MarketBeat Community Rating for Peregrine Pharmaceuticals (NASDAQ PPHM)
Community Ranking:  3.3 out of 5 (  )
Outperform Votes:  128 (Vote Outperform)
Underperform Votes:  64 (Vote Underperform)
Total Votes:  192
MarketBeat's community ratings are surveys of what our community members think about Peregrine Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Peregrine Pharmaceuticals (NASDAQ:PPHM) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $5.25 (14.13% upside)

Analysts' Ratings History for Peregrine Pharmaceuticals (NASDAQ:PPHM)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/6/2017Noble FinancialReiterated RatingBuyMediumView Rating Details
9/13/2016Roth CapitalReiterated RatingNeutral$3.50N/AView Rating Details
9/12/2016FBR & CoReiterated RatingOutperform$7.00N/AView Rating Details
(Data available from 7/23/2015 forward)

Earnings

Earnings History for Peregrine Pharmaceuticals (NASDAQ:PPHM)
Earnings by Quarter for Peregrine Pharmaceuticals (NASDAQ:PPHM)
Earnings History by Quarter for Peregrine Pharmaceuticals (NASDAQ PPHM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/14/2017Q4 2017($0.07)($0.16)$22.57 million$17.90 millionViewN/AView Earnings Details
3/13/2017Q3 2017($0.21)($0.28)$14.02 million$10.75 millionViewN/AView Earnings Details
12/12/2016Q217($0.21)($0.14)$587.49 million$23.40 millionViewN/AView Earnings Details
9/8/2016Q1($0.28)($0.35)$13.08 million$5.61 millionViewN/AView Earnings Details
7/14/2016Q416($0.21)($0.35)$15.80 million$18.78 millionViewListenView Earnings Details
3/9/2016Q316($0.49)($0.56)$7.96 million$6.71 millionViewListenView Earnings Details
12/10/2015Q216($0.63)($0.49)$7.35 million$9.52 millionViewListenView Earnings Details
9/9/2015Q116($0.56)($0.56)$7.96 million$9.67 millionViewN/AView Earnings Details
7/14/2015Q315($0.56)($0.49)$6.42 million$9.31 millionViewListenView Earnings Details
3/12/2015Q215($0.56)($0.56)$4.20 million$5.68 millionViewN/AView Earnings Details
12/10/2014Q115($0.49)($0.49)$5.82 million$6.30 millionViewN/AView Earnings Details
9/9/2014Q1($0.42)($0.56)$5.76 million$5.50 millionViewListenView Earnings Details
7/14/2014Q414($0.49)($0.42)$4.75 million$6.47 millionViewN/AView Earnings Details
3/7/2014Q314($0.42)($0.42)$5.09 million$3.90 millionViewN/AView Earnings Details
12/10/2013Q2($0.35)($0.35)$5.74 million$7.35 millionViewListenView Earnings Details
9/9/2013Q1 2014($0.35)($0.35)$4.75 million$4.69 millionViewN/AView Earnings Details
7/11/2013Q4 2013($0.42)($0.42)$3.57 million$4.25 millionViewN/AView Earnings Details
3/12/2013Q3 2013($0.49)($0.28)$3.90 million$7.04 millionViewN/AView Earnings Details
12/10/2012-0.08($0.63)($0.56)$4.03 million$4.03 millionViewN/AView Earnings Details
9/10/2012Q113($0.77)($0.49)$3.97 million$4.25 millionViewN/AView Earnings Details
7/16/2012($0.91)($0.70)ViewN/AView Earnings Details
3/9/2012($0.91)($0.91)ViewN/AView Earnings Details
12/12/2011($0.91)($1.12)ViewN/AView Earnings Details
9/9/2011($0.98)($0.77)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Peregrine Pharmaceuticals (NASDAQ:PPHM)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.05)($0.03)($0.04)
Q2 20171($0.04)($0.04)($0.04)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Peregrine Pharmaceuticals (NASDAQ:PPHM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Peregrine Pharmaceuticals (NASDAQ:PPHM)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Peregrine Pharmaceuticals (NASDAQ:PPHM)
Latest Headlines for Peregrine Pharmaceuticals (NASDAQ:PPHM)
Source:
DateHeadline
americanbankingnews.com logoPeregrine Pharmaceuticals Inc. (PPHM) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - July 23 at 12:00 AM
finance.yahoo.com logoPeregrine Pharmaceuticals, Inc. :PPHM-US: Earnings Analysis: Q4, 2017 By the Numbers : July 19, 2017
finance.yahoo.com - July 20 at 5:58 AM
finance.yahoo.com logoFeatured Company News – Amgen Submits Regulatory Applications in US, Europe to Include Overall Survival Data in KYPROLIS Label
finance.yahoo.com - July 18 at 7:30 AM
americanbankingnews.com logoPeregrine Pharmaceuticals Inc. (NASDAQ:PPHM) Announces Quarterly Earnings Results, Misses Estimates By $0.09 EPS
www.americanbankingnews.com - July 17 at 10:49 AM
americanbankingnews.com logoPeregrine Pharmaceuticals Inc. (PPHM) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - July 17 at 10:48 AM
seekingalpha.com logoPeregrine Pharmaceuticals' (PPHM) CEO Steven King on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - July 16 at 2:11 PM
marketwatch.com logoPeregrine Pharma shares drop after quarterly results fall short - MarketWatch
www.marketwatch.com - July 16 at 2:11 PM
finance.yahoo.com logoPeregrine Pharmaceuticals Reports Financial Results for Quarter and Fiscal Year Ended April 30, 2017 and Recent Developments
finance.yahoo.com - July 15 at 7:37 AM
finance.yahoo.com logoPeregrine Pharma shares drop after quarterly results fall short
finance.yahoo.com - July 15 at 7:37 AM
finance.yahoo.com logoPeregrine reports 4Q loss
finance.yahoo.com - July 15 at 7:37 AM
finance.yahoo.com logoEdited Transcript of PPHM earnings conference call or presentation 14-Jul-17 8:30pm GMT
finance.yahoo.com - July 15 at 7:37 AM
americanbankingnews.com logoHead to Head Review: MediWound (MDWD) & Peregrine Pharmaceuticals (NASDAQ:PPHM)
www.americanbankingnews.com - July 14 at 10:29 PM
finance.yahoo.com logoRonin Trading and SW Investment Management Issue Letter to Stockholders of Peregrine Pharmaceuticals
finance.yahoo.com - July 14 at 7:36 AM
finance.yahoo.com logoPeregrine Pharmaceuticals Issues Statement Regarding Ronin Trading and SW Investment Management’s Letter to Stockholders
finance.yahoo.com - July 14 at 7:36 AM
nasdaq.com logoITEK Disappoints, ALNY Maps Out ATLAS, ENTL Opens Wallet, D-day Nearing For OCUL - Nasdaq
www.nasdaq.com - July 11 at 6:46 AM
seekingalpha.com logoPeregrine Pharmaceuticals Preferreds: Yea Or Nay: Update - Seeking Alpha
seekingalpha.com - July 11 at 6:46 AM
finance.yahoo.com logoPeregrine Pharmaceuticals Announces Reverse Stock Split
finance.yahoo.com - July 8 at 1:42 PM
finance.yahoo.com logoPeregrine to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2017 After Market Close on July 14, 2017
finance.yahoo.com - July 8 at 1:42 PM
americanbankingnews.com logoComparing Peregrine Pharmaceuticals (PPHM) and Chiasma (CHMA)
www.americanbankingnews.com - July 7 at 12:10 AM
seekingalpha.com logoPeregrine Pharmaceuticals Preferreds: Yea Or Nay
seekingalpha.com - July 6 at 8:03 AM
americanbankingnews.com logoPeregrine Pharmaceuticals Inc. (PPHM) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - June 20 at 11:40 PM
nasdaq.com logoPeregrine Pharmaceuticals Series E Convertible Preferred Stock Ex-Dividend Reminder - Nasdaq
www.nasdaq.com - June 14 at 12:27 AM
finance.yahoo.com logoAvid Bioservices to Exhibit at the 2017 BIO International Convention
finance.yahoo.com - June 13 at 10:20 AM
americanbankingnews.com logoPeregrine Pharmaceuticals (PPHM) Downgraded by ValuEngine to "Sell"
www.americanbankingnews.com - June 9 at 3:22 PM
streetinsider.com logoPeregrine Pharma (PPHM) Announces Preliminary Correlative Analysis of PD-L1 Expression from SUNRISE Trial at ... - StreetInsider.com
www.streetinsider.com - June 6 at 12:56 AM
globenewswire.com logoPeregrine Pharmaceuticals Presents Preliminary Correlative Analysis of PD-L1 Expression from SUNRISE Trial at ... - GlobeNewswire (press release)
globenewswire.com - June 5 at 8:12 AM
finance.yahoo.com logoPeregrine Pharmaceuticals Presents Preliminary Correlative Analysis of PD-L1 Expression from SUNRISE Trial at ASCO 2017
finance.yahoo.com - June 5 at 8:12 AM
americanbankingnews.com logoPeregrine Pharmaceuticals (PPHM) Short Interest Up 21.9% in May
www.americanbankingnews.com - May 28 at 9:06 AM
nasdaq.com logoImplied Volatility Surging for Peregrine Pharmaceuticals (PPHM) Stock Options - Nasdaq
www.nasdaq.com - May 5 at 12:29 AM
americanbankingnews.com logoSomewhat Favorable Media Coverage Somewhat Likely to Affect Peregrine Pharmaceuticals (PPHM) Stock Price
www.americanbankingnews.com - May 4 at 9:24 PM
zacks.com logoImplied Volatility Surging for Peregrine Pharmaceuticals (PPHM) Stock Options
www.zacks.com - May 4 at 8:20 AM
finance.yahoo.com logoETFs with exposure to Peregrine Pharmaceuticals, Inc. : May 2, 2017
finance.yahoo.com - May 2 at 5:07 PM
finance.yahoo.com logoMilliporeSigma's Mobius(R) 2,000-liter Single-use Bioreactors to Expand Avid Bioservices' Manufacturing Capabilities
finance.yahoo.com - May 1 at 11:20 AM
americanbankingnews.com logoPeregrine Pharmaceuticals (PPHM) Short Interest Update
www.americanbankingnews.com - April 28 at 7:09 AM
americanbankingnews.com logoPeregrine Pharmaceuticals (PPHM) Earns Daily News Sentiment Rating of 0.36
www.americanbankingnews.com - April 27 at 5:26 PM
americanbankingnews.com logoPositive Media Coverage Likely to Impact Peregrine Pharmaceuticals (PPHM) Stock Price
www.americanbankingnews.com - April 24 at 5:46 PM
investorplace.com logoPeregrine Pharmaceuticals (PPHMP) Leads 14 Activist Investor Reports
investorplace.com - April 20 at 10:45 AM
americanbankingnews.com logoSomewhat Favorable News Coverage Likely to Affect Peregrine Pharmaceuticals (PPHM) Share Price
www.americanbankingnews.com - April 18 at 9:15 PM
finance.yahoo.com logoETFs with exposure to Peregrine Pharmaceuticals, Inc. : April 11, 2017
finance.yahoo.com - April 11 at 7:08 PM
americanbankingnews.com logoPeregrine Pharmaceuticals' (PPHM) "Buy" Rating Reiterated at Noble Financial
www.americanbankingnews.com - April 7 at 10:07 PM
finance.yahoo.com logoPeregrine Pharmaceuticals Highlights Clinical Data Presentation at AACR 2017 Annual Meeting Supporting Potential of Bavituximab to Enhance Anti-tumor Activity of Immunotherapy
finance.yahoo.com - April 7 at 12:00 PM
streetinsider.com logoPeregrine Pharma (PPHM) Announces Presentation of Preclinical ... - StreetInsider.com
www.streetinsider.com - April 4 at 4:47 AM
finance.yahoo.com logoPeregrine Pharmaceuticals Announces Presentation of Preclinical Study Results Highlighting Potential of PS-Targeting Antibodies to Enhance Anti-Tumor Activity of Adoptive T Cell Transfer Therapy with No Added Off-Target Toxicities
finance.yahoo.com - April 3 at 9:08 AM
finance.yahoo.com logoBiotech Industry Continues to Provide Investors with Gains in 2017: Today's Reports on Peregrine Pharmaceuticals and Novavax
finance.yahoo.com - March 27 at 9:39 AM
streetinsider.com logoPeregrine Pharma (PPHM) Says Five Abstracts Accepted for ... - StreetInsider.com
www.streetinsider.com - March 23 at 7:46 PM
streetinsider.com logoPeregrine Pharma (PPHM) Says Five Abstracts Accepted for Presentation at AACR
www.streetinsider.com - March 23 at 8:37 AM
finance.yahoo.com logoPeregrine Pharmaceuticals Announces Five Abstracts Accepted for Presentation at AACR 2017 Annual Meeting
finance.yahoo.com - March 23 at 8:37 AM
finance.yahoo.com logoAvid Bioservices Receives Mutliple 2017 CMO Leadership Awards for Quality, Reliability, Capabilties, Expertise and Compatibility
finance.yahoo.com - March 23 at 8:37 AM
finance.yahoo.com logoPEREGRINE PHARMACEUTICALS INC Financials
finance.yahoo.com - March 17 at 7:28 PM
seekingalpha.com logoPeregrine Pharmaceuticals' (PPHM) CEO Steve King on Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - March 14 at 10:10 AM

Social

Chart

Peregrine Pharmaceuticals (PPHM) Chart for Sunday, July, 23, 2017

This page was last updated on 7/23/2017 by MarketBeat.com Staff